Pharmacologic class (EPC) · 2 drug pages

Provitamin D2 compound: adverse event reports filed with FDA

14,390 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

14,390
reports across the class: 0.1% of all reports; 1,800
reports, 12 months to June 2026: 2,091 in the 12 months before; 89.9%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Provitamin D2 compound is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 14,390 adverse event reports received by FDA, 0.1% of the database, from April 2004 to June 2026.

1,800 reports arrived in the 12 months to June 2026, down 14% from 2,091 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 89.9% of the class's reports are marked serious, 21.8% record death among the outcomes and 43.5% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (23.7%), dyspnoea (21.4%) and pain (21.2%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Ergocalciferol	generic	10,074	1,544	93.1%	Drug ineffective
Vitamin d	generic	4,316	256	82.3%	Dyspnoea

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected23.7%3,408
Dyspnoeashortness of breath21.4%3,085
Painpain, site not specified21.2%3,055
Wheezingwheezing21.2%3,050
Asthmaasthma20.2%2,904
Off label useused for a purpose or in a way not on the label18.3%2,628
Fatiguetiredness17.9%2,581
Vomitingbeing sick16.8%2,416
Pneumonialung infection16.6%2,382
Headachehead pain14.4%2,065
Malaisegeneral feeling of being unwell14.3%2,061
Therapeutic product effect incomplete14.2%2,048
Drug hypersensitivityan allergic-type reaction to a medicine14.1%2,025
Nauseafeeling sick13.8%1,991
Condition aggravatedthe condition being treated got worse13.2%1,895
Hypertensionhigh blood pressure12.5%1,796
Drug intolerancethe medicine was not tolerated11.9%1,707
Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease11.7%1,677
Rashskin rash10.9%1,566
Arthralgiajoint pain10.9%1,563
Systemic lupus erythematosuslupus, an autoimmune disease10.8%1,558
Pyrexiafever10.7%1,533
Gastrooesophageal reflux diseaseacid reflux10.6%1,528
Psoriatic arthropathy10.5%1,517
Pain in extremitypain in an arm or leg10.4%1,501

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death21.8%3,134

Life-threatening20.5%2,946

Hospitalisation (initial or prolonged)43.5%6,265

Disability16.8%2,416

Congenital anomaly10%1,446

Other serious78.4%11,276

Not serious10.1%1,459

Patient age

Under 20.7%102

2 to 110.9%135

12 to 170.7%101

18 to 4419.3%2,773

45 to 6419.7%2,840

65 to 7417.9%2,578

75 and over8.4%1,208

Age not given32.3%4,653

Who reported

Physician17.7%2,542

Pharmacist2.5%364

Other health professional52.2%7,512

Lawyer0%7

Consumer or non-health professional25.3%3,646

Not given2.2%319

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Provitamin D2 compound reports

Which drugs are in the Provitamin D2 compound class on this site?

Ergocalciferol and Vitamin d. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

14,390 reports through June 2026, 1,800 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (23.7%), dyspnoea (21.4%), pain (21.2%), wheezing (21.2%) and asthma (20.2%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.